{"id":"bortezomib-rituximab","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"20-35","effect":"Neutropenia"},{"rate":"15-30","effect":"Anemia"},{"rate":"20-30","effect":"Nausea/vomiting"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bortezomib is a proteasome inhibitor that blocks protein degradation pathways, leading to accumulation of pro-apoptotic proteins and cancer cell death. Rituximab is a chimeric monoclonal antibody against CD20 that depletes B cells and enhances antibody-dependent cellular cytotoxicity. Together, they provide complementary mechanisms targeting both intrinsic apoptosis and B-cell malignancy.","oneSentence":"Bortezomib inhibits the proteasome to trigger cancer cell death, while rituximab targets CD20 on B cells to enhance immune-mediated tumor destruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:21.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":"Lymphoma","enrollment":95},{"nctId":"NCT01695941","phase":"PHASE1","title":"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-31","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07464210","phase":"PHASE2","title":"Nemtabrutinib, Bortezomib, and Rituximab for WM","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2026-06-01","conditions":"Waldenstrom Macroglobulinemia","enrollment":19},{"nctId":"NCT00492050","phase":"PHASE2","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08-02","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT02844322","phase":"PHASE4","title":"The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":35},{"nctId":"NCT04285268","phase":"PHASE2","title":"Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-05-06","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT06015750","phase":"PHASE4","title":"Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia","status":"WITHDRAWN","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-07-29","conditions":"Hypophosphatasia","enrollment":""},{"nctId":"NCT03620903","phase":"PHASE2","title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian Buske","startDate":"2019-09-11","conditions":"Waldenstrom Macroglobulinemia","enrollment":53},{"nctId":"NCT07200583","phase":"","title":"Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients","status":"COMPLETED","sponsor":"Ting YANG","startDate":"2025-05-31","conditions":"Hematologic Malignancies, Hematologic Disorders, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":50},{"nctId":"NCT00310037","phase":"PHASE2","title":"Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-06","conditions":"Mantle Cell Lymphoma","enrollment":151},{"nctId":"NCT05564052","phase":"PHASE2","title":"A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Lymphoma, Mantle-Cell","enrollment":36},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT03737136","phase":"NA","title":"Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2019-11-01","conditions":"Antibody-mediated Rejection","enrollment":20},{"nctId":"NCT07051850","phase":"","title":"Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2025-07-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma (MM)","enrollment":174},{"nctId":"NCT01350232","phase":"NA","title":"Treatment of Sickle Cell Anemia With Stem Cell Transplant","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-09","conditions":"Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia","enrollment":2},{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":373},{"nctId":"NCT06796517","phase":"","title":"Immunotherapy in Lymphoma","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2024-06-26","conditions":"Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed","enrollment":72},{"nctId":"NCT03129828","phase":"PHASE1, PHASE2","title":"Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2","status":"COMPLETED","sponsor":"Prof. Dr. Clemens Schmitt","startDate":"2017-03-17","conditions":"Diffuse Large B Cell Lymphoma","enrollment":38},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT01788020","phase":"PHASE3","title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2013-11","conditions":"Waldenström's Macroglobulinemia","enrollment":202},{"nctId":"NCT04083014","phase":"PHASE2","title":"Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2019-08-20","conditions":"Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia","enrollment":33},{"nctId":"NCT00863369","phase":"PHASE1, PHASE2","title":"Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2005-06-29","conditions":"Lymphoma","enrollment":33},{"nctId":"NCT04626791","phase":"PHASE2","title":"Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-08-03","conditions":"Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT03697356","phase":"PHASE2","title":"R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia","status":"RECRUITING","sponsor":"Kosin University Gospel Hospital","startDate":"2019-03-06","conditions":"Waldenström's Macroglobulinemia","enrollment":54},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT04224571","phase":"PHASE2","title":"CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2018-09-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse","enrollment":208},{"nctId":"NCT01267812","phase":"PHASE2","title":"Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-10-03","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT01216683","phase":"PHASE2","title":"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-09","conditions":"Lymphoma","enrollment":289},{"nctId":"NCT04433156","phase":"PHASE2","title":"VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2020-04-22","conditions":"Marginal Zone Lymphoma","enrollment":60},{"nctId":"NCT00114738","phase":"PHASE2","title":"EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-06-15","conditions":"Lymphoma, Mantle Cell, Mantle Cell Lymphoma","enrollment":53},{"nctId":"NCT01805557","phase":"PHASE2, PHASE3","title":"Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2013-02-04","conditions":"Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":108},{"nctId":"NCT00477412","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-03","conditions":"Mantle Cell Lymphoma","enrollment":107},{"nctId":"NCT01381692","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-20","conditions":"Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma","enrollment":9},{"nctId":"NCT01592981","phase":"PHASE2","title":"Randomised Trial in Waldenstrom's Macroglobulinaemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-01","conditions":"Waldenstrom's Macroglobulinaemia","enrollment":60},{"nctId":"NCT01046006","phase":"PHASE2","title":"Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"Meletios A. Dimopoulos","startDate":"2007-03","conditions":"Waldenstrom's Macroglobulinemia","enrollment":59},{"nctId":"NCT01125293","phase":"PHASE1, PHASE2","title":"Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2010-04","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT02371148","phase":"PHASE2","title":"Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-06","conditions":"Waldenstrom's Macroglobulinemia","enrollment":38},{"nctId":"NCT00422799","phase":"PHASE2","title":"Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2006-08-30","conditions":"Waldenstrom's Macroglobulinemia","enrollment":63},{"nctId":"NCT01460602","phase":"PHASE1, PHASE2","title":"Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2010-05","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":""},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00889798","phase":"","title":"Tumor Registry of Lymphatic Neoplasia","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2009-04","conditions":"Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)","enrollment":3795},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT00980395","phase":"PHASE2","title":"Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2009-07-07","conditions":"Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma","enrollment":24},{"nctId":"NCT00581776","phase":"PHASE2","title":"Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-05","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT00439556","phase":"PHASE2","title":"Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-02-13","conditions":"CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm","enrollment":40},{"nctId":"NCT00369707","phase":"PHASE2","title":"Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2006-08-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":42},{"nctId":"NCT00372905","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2007-07-24","conditions":"Lymphoma","enrollment":18},{"nctId":"NCT02500251","phase":"PHASE1, PHASE2","title":"Belimumab Impacting Transplant Eligibility","status":"COMPLETED","sponsor":"E. Steve Woodle","startDate":"2015-06","conditions":"Renal Transplant Rejection","enrollment":11},{"nctId":"NCT00711828","phase":"PHASE2","title":"Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08","conditions":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":21},{"nctId":"NCT03700229","phase":"PHASE2","title":"Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2018-10-10","conditions":"Acquired Hemophilia A","enrollment":22},{"nctId":"NCT00295932","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-12-13","conditions":"Leukemia, Lymphoma","enrollment":79},{"nctId":"NCT01848132","phase":"PHASE2","title":"Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2013-10-03","conditions":"Diffuse, Large B-Cell, Lymphoma","enrollment":121},{"nctId":"NCT00413959","phase":"PHASE2","title":"VELCADE,Rituximab,Cyclophosphamide and Decadron","status":"TERMINATED","sponsor":"Oncology Specialists, S.C.","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, B-Cell","enrollment":12},{"nctId":"NCT00169468","phase":"PHASE2","title":"Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2005-01","conditions":"B Cell Lymphoma","enrollment":48},{"nctId":"NCT00722137","phase":"PHASE3","title":"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2008-05-01","conditions":"Mantle Cell Lymphoma","enrollment":487},{"nctId":"NCT00151320","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":76},{"nctId":"NCT01556347","phase":"PHASE2","title":"Multi-Drug Desensitization Protocol for Heart Transplant Candidates","status":"TERMINATED","sponsor":"Providence Health & Services","startDate":"2012-07","conditions":"Heart Transplantation","enrollment":2},{"nctId":"NCT00201877","phase":"PHASE2","title":"Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2004-12","conditions":"Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":25},{"nctId":"NCT03443570","phase":"PHASE3","title":"Rituximab Combining Bortezomib Versus Rituximab in Management of ITP","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-03-01","conditions":"Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic","enrollment":200},{"nctId":"NCT01058239","phase":"PHASE2","title":"Bortezomib Plus Rituximab for EBV+ PTLD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2011-11","conditions":"Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant)","enrollment":7},{"nctId":"NCT00772668","phase":"NA","title":"Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL","status":"TERMINATED","sponsor":"University of Miami","startDate":"2009-09-25","conditions":"Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":3},{"nctId":"NCT00869323","phase":"PHASE2","title":"Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-03","conditions":"Lymphoproliferative Disorder","enrollment":3},{"nctId":"NCT00376961","phase":"PHASE2","title":"S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2006-08","conditions":"Lymphoma","enrollment":68},{"nctId":"NCT01439750","phase":"PHASE1","title":"Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)","status":"UNKNOWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2012-05","conditions":"Mantle Cell Lymphoma","enrollment":13},{"nctId":"NCT01226849","phase":"PHASE1","title":"Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2010-11","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":6},{"nctId":"NCT00504751","phase":"PHASE2","title":"Phase II Study of \"VIPER\" Chemotherapy in Rel/Ref DLBCL","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":15},{"nctId":"NCT01449344","phase":"PHASE3","title":"Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL","status":"UNKNOWN","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2009-05-09","conditions":"Mantle Cell Lymphoma","enrollment":128},{"nctId":"NCT00633594","phase":"PHASE1, PHASE2","title":"Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2008-06","conditions":"Mantle Cell Lymphoma","enrollment":39},{"nctId":"NCT00931918","phase":"PHASE2","title":"Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2009-10","conditions":"Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":206},{"nctId":"NCT00334438","phase":"PHASE1","title":"Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-07","conditions":"Lymphoma","enrollment":12},{"nctId":"NCT02971982","phase":"PHASE1, PHASE2","title":"PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2016-10","conditions":"Treatment","enrollment":40},{"nctId":"NCT00634179","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of VR-CHOP in Lymphoma Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-02","conditions":"Lymphoma, B-Cell, Follicular Lymphoma","enrollment":37},{"nctId":"NCT01186458","phase":"PHASE2","title":"Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Hoosier Cancer Research Network","startDate":"2010-10","conditions":"Lymphoma, Non-Hodgkin","enrollment":4},{"nctId":"NCT01929980","phase":"PHASE2","title":"Bortezomib to Treat Significant Complication of HSCT","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2012-07","conditions":"Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s)","enrollment":4},{"nctId":"NCT01029730","phase":"PHASE2","title":"Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-03","conditions":"Lymphoma","enrollment":55},{"nctId":"NCT01599949","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Mantle Cell Lymphoma","enrollment":120},{"nctId":"NCT02525172","phase":"PHASE4","title":"Immune Modulation Therapy for Pompe Disease","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2015-08","conditions":"Pompe Disease","enrollment":8},{"nctId":"NCT01324596","phase":"PHASE3","title":"A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2011-04","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":1132},{"nctId":"NCT00250926","phase":"PHASE2","title":"Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-10","conditions":"Waldenstrom's Macroglobulinemia","enrollment":23},{"nctId":"NCT00908583","phase":"PHASE4","title":"Desensitization in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-05","conditions":"HLA Sensitization","enrollment":44},{"nctId":"NCT00740415","phase":"PHASE2","title":"Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2007-06","conditions":"Lymphoma","enrollment":39},{"nctId":"NCT01457144","phase":"PHASE2","title":"Study of Mantle Cell Lymphoma Treatment by RiBVD","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2011-10","conditions":"Mantle Cell Lymphoma","enrollment":76},{"nctId":"NCT00771875","phase":"PHASE2","title":"Randomized Trial for Mixed Acute Rejection","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-09","conditions":"Graft Rejection","enrollment":30},{"nctId":"NCT00782821","phase":"PHASE4","title":"Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-09","conditions":"Kidney Transplantation","enrollment":40},{"nctId":"NCT02563340","phase":"PHASE1, PHASE2","title":"Effect of BM-MSCs on Chronic AMR After Kidney Transplantation","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-11","conditions":"Kidney Transplantation","enrollment":60},{"nctId":"NCT01119794","phase":"PHASE2","title":"Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab","status":"TERMINATED","sponsor":"Brown University","startDate":"2010-07","conditions":"Lymphoma, Non-Hodgkins","enrollment":10},{"nctId":"NCT00547534","phase":"PHASE2","title":"Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2007-10","conditions":"Non-Hodgkin's Lymphoma","enrollment":31},{"nctId":"NCT01497275","phase":"PHASE2","title":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2012-02","conditions":"Mantle-Cell Lymphoma","enrollment":5},{"nctId":"NCT00958256","phase":"PHASE2","title":"Study of Bortezomib in Combination With Cyclophosphamide and Rituximab","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-08","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":22},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00832234","phase":"PHASE2","title":"Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2006-09","conditions":"Waldenstroms Macroglobulinemia","enrollment":59},{"nctId":"NCT00433537","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-05","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma","enrollment":77},{"nctId":"NCT00851552","phase":"PHASE2","title":"Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-01","conditions":"Lymphoma","enrollment":9},{"nctId":"NCT00510887","phase":"PHASE2","title":"Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-01","conditions":"Lymphoma, Follicular","enrollment":14},{"nctId":"NCT01902862","phase":"PHASE2","title":"An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2006-02","conditions":"Lymphoma, Follicular","enrollment":7},{"nctId":"NCT01040871","phase":"PHASE2","title":"Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2010-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":164}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":2,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":2,"reaction":"RENAL FAILURE"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ANAPHYLACTIC REACTION"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"COVID-19"},{"count":1,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":1,"reaction":"DECREASED APPETITE"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bortezomib + rituximab","genericName":"bortezomib + rituximab","companyName":"Jonsson Comprehensive Cancer Center","companyId":"jonsson-comprehensive-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bortezomib inhibits the proteasome to trigger cancer cell death, while rituximab targets CD20 on B cells to enhance immune-mediated tumor destruction. Used for B-cell non-Hodgkin lymphoma, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}